Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price target of $19.33 for the company and are forecasting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given Aileron Therapeutics an industry rank of 179 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th.
A number of hedge funds have recently modified their holdings of the business. Nexthera Capital LP bought a new stake in Aileron Therapeutics during the 2nd quarter valued at $1,272,000. Goldman Sachs Group Inc. bought a new stake in Aileron Therapeutics during the 2nd quarter valued at $418,000. Laurion Capital Management LP bought a new stake in Aileron Therapeutics during the 2nd quarter valued at $335,000. Neuberger Berman Group LLC bought a new stake in Aileron Therapeutics during the 2nd quarter valued at $279,000. Finally, Citadel Advisors LLC bought a new stake in Aileron Therapeutics during the 2nd quarter valued at $141,000. 7.64% of the stock is currently owned by institutional investors and hedge funds.
Aileron Therapeutics (NASDAQ ALRN) traded down $0.41 during trading hours on Friday, hitting $9.21. 36,697 shares of the company were exchanged, compared to its average volume of 35,742. The company has a market cap of $129.75 and a PE ratio of -6.58. Aileron Therapeutics has a 52 week low of $8.77 and a 52 week high of $15.48.
Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.07). research analysts expect that Aileron Therapeutics will post -1.76 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/20/zacks-aileron-therapeutics-inc-alrn-given-19-33-consensus-target-price-by-brokerages.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.